Your browser doesn't support javascript.
loading
Impact of a Hyperkalemia Protocol Tailored to Glucose Concentration and Renal Function on Insulin-Induced Hypoglycemia in Patients with Low Pretreatment Glucose.
Dybdahl, Daniel; Roberson, Taylor; Rasor, Emily; Kline, Laura; Pershing, Michelle.
Afiliação
  • Dybdahl D; Department of Pharmacy, OhioHealth Grant Medical Center, Columbus, Ohio.
  • Roberson T; Department of Pharmacy, OhioHealth Grant Medical Center, Columbus, Ohio.
  • Rasor E; Department of Pharmacy, OhioHealth Grant Medical Center, Columbus, Ohio.
  • Kline L; Department of Pharmacy, OhioHealth Riverside Methodist Hospital, Columbus, Ohio.
  • Pershing M; Department of Research, OhioHealth Research Institute, Columbus, Ohio.
J Emerg Med ; 66(4): e421-e431, 2024 Apr.
Article em En | MEDLINE | ID: mdl-38462394
ABSTRACT

BACKGROUND:

Hyperkalemia is a common electrolyte abnormality that requires urgent treatment. Insulin is an effective treatment for hyperkalemia, but risk factors for developing insulin-induced hypoglycemia exist (e.g., low pretreatment glucose or renal impairment).

OBJECTIVE:

This study evaluated the impact of a hyperkalemia protocol tailored to glucose concentration and renal function on insulin-induced hypoglycemia.

METHODS:

This was a retrospective cohort study of emergency department patients with glucose ≤ 100 mg/dL treated with insulin for hyperkalemia. The primary outcome was incidence of hypoglycemia in patients treated prior to (July 1, 2018-June 30, 2019) vs. after (January 1, 2020-December 31, 2020) the protocol update, which individualized insulin and dextrose doses by glucose concentration and renal function. Secondary outcomes included change in potassium and protocol safety. We assessed factors associated with hypoglycemia using multiple logistic regression.

RESULTS:

We included 202 total patients (preimplementation 114, postimplementation 88). Initial insulin dose was lower in the postimplementation group (p < 0.001). We found a nonsignificant reduction in hypoglycemia in the postimplementation group (42.1% vs. 30.7%, p = 0.10). Degree of potassium reduction was similar in patients who received insulin 5 units vs. 10 units (p = 0.72). Higher pretreatment glucose (log odds ratio [OR] -0.05, 95% confidence interval [CI] -0.08 to -0.02) and additional insulin administration (log OR -1.55, 95% CI -3.01 to -0.25) were associated with reduced risk of developing hypoglycemia.

CONCLUSION:

A hyperkalemia protocol update was not associated with a significant reduction in hypoglycemia, and the incidence of hypoglycemia remained higher than anticipated. Future studies attempting to optimize treatment in this high-risk population are warranted.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hiperpotassemia / Hipoglicemia / Insulina Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hiperpotassemia / Hipoglicemia / Insulina Idioma: En Ano de publicação: 2024 Tipo de documento: Article